Compare COHU & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | TSHA |
|---|---|---|
| Founded | 1947 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1994 | 2020 |
| Metric | COHU | TSHA |
|---|---|---|
| Price | $32.18 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $34.00 | $10.78 |
| AVG Volume (30 Days) | 517.7K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,956,000.00 | $9,773,000.00 |
| Revenue This Year | $14.38 | N/A |
| Revenue Next Year | $19.12 | $1,228.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.74 | ★ 17.28 |
| 52 Week Low | $12.80 | $1.13 |
| 52 Week High | $34.96 | $6.02 |
| Indicator | COHU | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 47.99 |
| Support Level | $27.53 | $4.33 |
| Resistance Level | $34.96 | $5.31 |
| Average True Range (ATR) | 1.72 | 0.26 |
| MACD | 0.22 | -0.00 |
| Stochastic Oscillator | 86.75 | 53.97 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.